|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Update on hepatitis B virus infection显示文摘Chronic infection with hepatitis B virus(HBV) leads to the development of hepatocellular carcinoma and/or chronic liver failure. Despite extensive research, the immunopathogenesis is not completely understood. Viral persistence and clinical outcomes following HBV infection depend on viral factors and host factors; including genetic factors that determine a host's immune mechanisms. The primary goal of chronic hepatitis B(CHB)treatment is to eradicate HBV or to at least maintain suppression of HBV replication. Despite recent advances in anti-viral agents for chronic HBV infection, complete eradication of the virus has been difficult to achieve.Agents for the treatment of CHB are divided mainly into two groups: immunomodulating agents and antiviral nucleos(t)ide analogues(NAs). Although NAs are safe,effective and easily administered orally, their long-term use poses the risk of drug resistance. Currently, international evidence-based guidelines have been developed to support physicians in managing CHB patients.However, treatment of patients with drug resistance is still challenging, as only a few classes of anti-HBV drugs are available and cross-resistance between drugs can occur. In addition, as the currently available genotypictest for detection of drug resistance still has limitations in identifying the different substitutions present in the same viral genome, the development of a new virologic test to overcome this limitation is necessary. Among the predictive factors associated with response to pegylated interferon(PEG-IFN) therapy, hepatitis B surface antigen quantification is considered to be a surrogate marker for monitoring response to PEG-IFN. Current practice guidelines stress the importance of profound and durable HBV viral suppression in the treatment of CHB patients. To this end, it is essential to choose a potent antiviral drug with a low risk of resistance for initial treatment of CHB to achieve sustained virological response. This review highlights recent advances in the understanding of the immunopathogenesis of HBV and currently available and developing treatment strategies against HBV infection. | Chan Ran You Sung Won Lee Jeong Won Jang Seung Kew Yoon | 2014 | World Journal of Gastroenterology2014，20，37： | 7 |
| 2 | Is the AIM65 score useful in predicting outcomes in peptic ulcer bleeding?显示文摘AIM:To evaluate the applicability of AIMS65 scores in predicting outcomes of peptic ulcer bleeding.METHODS:This was a retrospective study in a single center between January 2006 and December 2011.We enrolled 522 patients with upper gastrointestinal haemorrhage who visited the emergency room.Highrisk patients were regarded as those who had rebleeding within 30 d from the first endoscopy as well as those who died within 30 d of visiting the Emergency room.A total of 149 patients with peptic ulcer bleeding were analysed,and the AIMS65 score was used to retrospectively predict the high-risk patients.RESULTS:A total of 149 patients with peptic ulcer bleeding were analysed.The poor outcome group comprised 28 patients[male:23(82.1%)vs female:5(10.7%)]while the good outcome group included 121patients[male:93(76.9%)vs female:28(23.1%)].The mean age in each group was not significantly different.The mean serum albumin levels in the poor outcome group were slightly lower than those in the good outcome group(P=0.072).For the prediction of poor outcome,the AIMS65 score had a sensitivity of35.5%(95%CI:27.0-44.8)and a specificity of 82.1%(95%CI:63.1-93.9)at a score of 0.The AIMS65 score was insufficient for predicting outcomes in peptic ulcer bleeding(area under curve=0.571;95%CI:0.49-0.65).CONCLUSION:The AIMS65 score may therefore not be suitable for predicting clinical outcomes in peptic ulcer bleeding.Low albumin levels may be a risk factor associated with high mortality in peptic ulcer bleeding. | Sung Hoon Jung Jung Hwan Oh Hye Yeon Lee Joon Won Jeong Se Eun Go Chan Ran You Eun Jung Jeon Sang Wook Choi | 2014 | World Journal of Gastroenterology2014，20，7： | 6 |
| 3 | Severe thrombocytopenia before liver transplantation is associated with delayed recovery of thrombocytopenia regardless of donor type显示文摘AIM: To compare the recovery of thrombocytopenia and splenomegaly during long-term follow-up after liver transplantation in patients receiving a living donor transplant or a cadaveric donor transplant. METHODS: This was a retrospective cohort study of 216 consecutive liver transplant patients who survived for > 6 mo after transplantation; 169 received a liver transplant from a living donor and 47 from a cadaveric donor. The platelet counts or spleen volumes were examined before transplant, 1, 6, and 12 mo after transplant, and then annually until 5 years after transplant. RESULTS: The mean follow-up period was 49 mo (range, 21-66). Platelet counts increased continu-ously for 5 years after orthotopic liver transplant. The restoration of platelet counts after transplant was sig-nificantly slower in patients with severe pretransplant thrombocytopenia (< 50 000/μL) until 4 years after transplant (P = 0.005). Donor type did not significantly affect the recovery of platelet count and spleen vol-ume in either patient group. In multivariate analysis, pretransplant severe thrombocytopenia (< 50 000/μL) was an independent factor associated with sustained thrombocytopenia (P < 0.001, odds ratio 6.314; con-fidence interval, 2.828-14.095). Thrombocytopenia re-appeared after transplant in seven patients with portal flow disturbance near the anastomosis site. CONCLUSION: Our study suggests that severe throm-bocytopenia before transplant is closely associated with delayed recovery of platelet count after transplant and donor type did not affect the recovery of throm-bocytopenia. The reappearance of thrombocytopenia after transplant should be considered a possible indica-tor of flow disturbance in the portal vein. | Jae Hyuck Chang Jong Young Choi Hyun Young Woo Jung Hyun Kwon Chan Ran You Si Hyun Bae Seung Kew Yoon Myung-Gyu Choi In-Sik Chung Dong Goo Kim | 2008 | World Journal of Gastroenterology2008，14，37： | 2 |
| 4 | Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma显示文摘 | Jeong Won Jang Byong Sun Oh Jung Hyun Kwon Chan Ran You Kyu Won Chung Chul Seung Kay Hyun Suk Jung | 2012 | Cytokine2012，，3： | 2 |
| 5 | Efficacy of transarterial chemolipiodolization with or without 3-dinmensional conformal radiotherapy for huge HCC with portal vein tumor Thrombosis显示文摘 | Chan Ran You Jeong Won Jang | 2007 | Korean J Hepatol2007，13，3： | 1 |
| 6 | Clinical features and predictors of clinical outcomes in K orean patients with C rohn’s disease: A K orean A ssociation for the S tudy of I ntestinal D iseases multicenter study显示文摘 | Chang Mo Moon Dong Il Park Eun Ran Kim Young‐Ho Kim Chang Kyun Lee Suck‐Ho Lee Jae Hak Kim Kyu‐Chan Huh Sung‐Ae Jung Soon Man Yoon Hyun Joo Song Hyun Joo Jang You Sun Kim Kang‐Moon Lee Jeong Eun Shin | 2014 | J Gastroenterol Hepatol2014，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员